We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · January 14, 2021

18F-PSMA-1007 PET/CT for Response Assessment in Patients With mRCC Undergoing Systemic Therapy

European journal of nuclear medicine and molecular imaging

 

Additional Info

European journal of nuclear medicine and molecular imaging
18F-PSMA-1007 PET/CT for Response Assessment in Patients With Metastatic Renal Cell Carcinoma Undergoing Tyrosine Kinase or Checkpoint Inhibitor Therapy: Preliminary Results
Eur. J. Nucl. Med. Mol. Imaging 2020 Dec 28;[EPub Ahead of Print], LM Mittlmeier, M Unterrainer, S Rodler, A Todica, NL Albert, C Burgard, CC Cyran, WG Kunz, J Ricke, P Bartenstein, CG Stief, H Ilhan, M Staehler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading